The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).
 
Winette T.A. Van Der Graaf
Consulting or Advisory Role - Bayer; Bayer (I)
Speakers' Bureau - Bayer (I)
 
Myrella Vlenterie
No Relationships to Disclose
 
Neeltje Steeghs
Research Funding - AB Science (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Ingrid Desar
Consulting or Advisory Role - Eisai (Inst); Lilly (Inst)
 
Remy B Verheijen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Anne Miek Koenen
No Relationships to Disclose
 
Willem Grootjans
No Relationships to Disclose
 
Lioe-Fee de Geus-Oei
Research Funding - GE Healthcare (Inst); Philips Healthcare (Inst); Siemens (Inst)
 
Wim J.G. Oyen
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer
 
Nielka P. Van Erp
Speakers' Bureau - Sichmann
Research Funding - Astellas Oncology (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)